Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell Progenitor Product SMART 101 (ProTcell™) for AML and ALL

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling